You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Charlotte, North Carolina 28232

  • Kidney Cancer


RATIONALE: Biological therapies use different ways to stimulate the immune system to try to stop cancer cells from growing. Combining interferon alfa and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer.

Study summary:

OBJECTIVES: - Evaluate the response and disease-free survival of patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 and interferon alfa. - Assess the toxicity of this regimen. OUTLINE: Patients undergo nephrectomy if the diseased kidney makes up the bulk of the tumor burden. All patients receive subcutaneous interferon alfa on day 1 and interleukin-2 on days 3-5 of week 1, followed by reduced doses of interferon alfa and interleukin-2 on days 1, 3, and 5 of weeks 2-6. Patients are assessed for response approximately 2 months after initiating therapy. Patients with stable or responding disease undergo a second course; those who continue to respond may receive additional therapy provided toxicity is limited. Patients are followed for survival. PROJECTED ACCRUAL: 14 patients will be entered.


DISEASE CHARACTERISTICS: - Histologically proven renal cell cancer that is metastatic - No greater than 50% estimated hepatic replacement by tumor on CT or MRI - No symptomatic involvement of the CNS or a major nerve - Measurable disease required - Ineligible for treatment with low-dose interleukin-2 on another CMC protocol PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 50%-100% Life expectancy: - More than 3 months Hematopoietic: - No coagulopathy (i.e., platelet count less than 80,000/mm3) Hepatic: - AST and ALT no greater than 5 times normal Renal: - Creatinine less than 4.0 mg/dL Cardiovascular: - No symptomatic angina - No untreated coronary artery disease - No refractory arrhythmia - No abnormal left ventricular function Pulmonary: - No dyspnea on minimal exertion Other: - No site of ongoing bleeding - No systemic infection - No HIV antibody - No HBsAg - No requirement for steroids - No psychiatric disease that precludes informed consent or protocol treatment - No second malignancy except: - Basal cell skin carcinoma - Carcinoma in situ of the cervix - Not pregnant or nursing - Effective contraception required of fertile women PRIOR CONCURRENT THERAPY: Biologic therapy - No prior interleukin-2 Chemotherapy - Not specified Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified Other - At least 28 days since prior treatment for renal cell cancer



Primary Contact:

Study Chair
Richard L. White, MD
Blumenthal Cancer Center at Carolinas Medical Center

Backup Contact:


Location Contact:

Charlotte, North Carolina 28232
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 07, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.